BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Telitacicept readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Telitacicept\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06654596-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase na readout est. (NCT06654596)
DESCRIPTION:Telitacicept\, phase na\, IgA Nephropathy.\nStudy: Efficacy and
  Safety of Telitacicept in IgAN\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06654596
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355257-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Telitacicept: Phase 2/3 readout est. (NCT07355257)
DESCRIPTION:Telitacicept\, phase 2/3.\nStudy: TELITACICEPT IN INFLAMMATORY 
 MYOPATHIES(TELITACICEPT-IM)\nEstimated primary completion: 30 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07355257
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249632-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07249632)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: A Study of Telitacicept in Pati
 ents With Ocular Myasthenia Gravis (OMG)\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07249632
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05962840-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase 4 readout est. (NCT05962840)
DESCRIPTION:Telitacicept\, phase 4.\nStudy: Efficacy and Safety for Rituxim
 ab Combined With Telitacicept in the Treatment of ANCA-associated Vasculit
 is (TTCAAVREM)\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05962840
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375005-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Telitacicept: Phase 2 readout est. (NCT06375005)
DESCRIPTION:Telitacicept\, phase 2.\nStudy: Efficacy and Safety of Telitaci
 cept in the Treatment of Systemic Sclerosis\nEstimated primary completion:
  6 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teli
 tacicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06375005
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886476-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Telitacicept: Phase 1 readout est. (NCT07886476)
DESCRIPTION:Telitacicept\, phase 1\, IgA Nephropathy.\nStudy: IBI3034 Study
  in Healthy Adults and Patients With Primary IgA Nephropathy\nEstimated pr
 imary completion: 31 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/telitacicept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07886476
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456580-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Telitacicept: Phase 3 readout est. (NCT06456580)
DESCRIPTION:Telitacicept\, phase 3\, Generalized Myasthenia Gravis.\nStudy:
  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravi
 s (UPSTREAM MG)\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456580
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111338-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07111338)
DESCRIPTION:Telitacicept\, phase 2.\nStudy: Telitacicept for PGNMID: A Sing
 le-Arm Study\nEstimated primary completion: 29 May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07111338
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052981-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07052981)
DESCRIPTION:Telitacicept\, phase 3\, IgA Nephropathy.\nStudy: Clinical Stud
 y on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric
  IgA Nephropathy or IgA Vasculitis Nephritis\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07052981
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597733-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Telitacicept: Phase na readout est. (NCT07597733)
DESCRIPTION:Telitacicept\, phase na.\nStudy: Telitacicept for Refractory Ch
 ronic Inflammatory Demyelinating Polyneuropathy\nEstimated primary complet
 ion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 telitacicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07597733
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836660-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07836660)
DESCRIPTION:Telitacicept\, phase 2\, Sjögren's Disease.\nStudy: A Study of
  IBI355 in Participants With Moderate-to-Severe Sjögren's Disease\nEstima
 ted primary completion: 1 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07836660
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796516-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07796516)
DESCRIPTION:Telitacicept\, phase 2\, Rheumatoid Arthritis.\nStudy: Efficacy
  and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arth
 ritis\nEstimated primary completion: 30 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07796516
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902609-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07902609)
DESCRIPTION:Telitacicept\, phase 2.\nStudy: Sequential Daratumumab Followed
  by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A 
 Phase IIa Clinical Trial\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07902609
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522099-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07522099)
DESCRIPTION:Telitacicept\, phase 2\, IgA Nephropathy.\nStudy: Chinese Adult
 s With Kidney Disease\nEstimated primary completion: 10 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07522099
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404865-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07404865)
DESCRIPTION:Telitacicept\, phase 3\, Sjögren's Disease.\nStudy: Phase 3 St
 udy of Telitacicept in Active Primary Sjögren's Disease\nEstimated primar
 y completion: December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/telitacicept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07404865
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298928-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telitacicept: Phase na readout est. (NCT07298928)
DESCRIPTION:Telitacicept\, phase na.\nStudy: A Study on the Efficacy and Sa
 fety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07298928
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495033-5453@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07495033)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: Phase III Clinical Trial of Tel
 itacicept Injection in the Treatment of Patients With Connective Tissue Di
 sease-related Interstitial Lung Disease\nEstimated primary completion: 31 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicep
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 495033
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
